Metabasis Therapeutics (MBRX) Reports Q2 Loss of $0.34, Beats by 2c
More News related to MBRX
- Morning Movers 6/11: STAA, CPST, HGSI, CHDX, MBRX, OBCI Higher; LULU, UNH, LUB, LTON, PNFP Lower
- STAA, MBRX, NPSP, HGSI, CPST, JAZZ, ESLR See Volume and Upside Price Action
- After-Hours Movers 6/10: MBRX, PALM, PLXS Higher; ATPG, ATU, VMC, LUB Lower
- Metabasis (MBRX) To Receive $6M Fee From Merck, But Still Warns About Its Future
- Metabasis Therapeutics Announces That Its Collaborator Merck & Co., Inc. Has Selected a Lead AMPK Activator for Late Preclinical Development and Has Agreed to Make a One-Time Payment for All Remai
Metabasis Therapeutics (Nasdaq: MBRX) reports a Q2 loss of $0.34, 2 cents better than the analyst estimate of ($0.36). Revenues for the quarter were $700K, versus the consensus of $1.24 million.
Related Categories
EarningsStocks Mentioned
-0.07Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
